Biontech sales exceed two billion euros in the first quarter

2.05 billion euros in sales were made by the Mainz-based company Biontech in the first quarter of 2021, compared to 27.7 million euros in the same period last year.

If there is a clear winner in the Corona pandemic, it is the pharmaceutical industry. This is also felt by Biontech, a company based in Mainz, Germany, which published its figures for the first quarter of 2021 on Thursday: sales rose from 27.7 million euros in the first quarter of 2020 to 2.05 billion euros. A quarterly loss of 58 million euros turned into a profit of 1.13 billion euros.

As of May 6, Biontech and its U.S. partner Pfizer had shipped 450 million doses of the Covid-19 vaccine worldwide. This year's shipments are expected to total three billion doses of the vaccine, and firm contracts have already been signed for years after that to secure sales of the Covid-19 vaccine.

Biontech expects sales of 12.4 billion euros this year. The pharmaceutical company plans to put the revenue mainly into further research on the mRNA agents, which are also used for the Covid-19 vaccines and will be used in cancer therapy. In addition, Biontech also wants to produce vaccine in China and has signed a letter of intent for a joint venture for this purpose. So far, the Mainz-based company's vaccine has not yet been approved there.